CR20210556A - Quelantes macrocíclicos y métodos de uso de estos - Google Patents

Quelantes macrocíclicos y métodos de uso de estos

Info

Publication number
CR20210556A
CR20210556A CR20210556A CR20210556A CR20210556A CR 20210556 A CR20210556 A CR 20210556A CR 20210556 A CR20210556 A CR 20210556A CR 20210556 A CR20210556 A CR 20210556A CR 20210556 A CR20210556 A CR 20210556A
Authority
CR
Costa Rica
Prior art keywords
radioimmunoconjugates
radiometal
methods
alpha
macrocyclic
Prior art date
Application number
CR20210556A
Other languages
English (en)
Inventor
Vadim Dudkin
Wei Zhang
Rhys Salter
John Keith
Shalom Goldberg
Fengbin Song
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CR20210556A publication Critical patent/CR20210556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan quelantes macrocíclicos (I) para la quelación de iones de radiometal emisores alfa, tales como actinio-225. También se proporcionan complejos de radiometal que contienen un ion de radiometal emisor alfa unido al quelante macrocíclico a través de enlace coordinado, y radioinmunoconjugados que contienen los complejos de radiometal unidos covalentemente a un ligando dirigido, tal como un anticuerpo o fragmento de unión al antígeno de este. Los radioinmunoconjugados pueden producirse mediante reacciones químicas clic. También se describen métodos para usar los radiocomplejos y radioinmunoconjugados para dirigirse selectivamente a células neoplásicas para radioterapia y para tratar enfermedades y trastornos neoplásicos.
CR20210556A 2019-05-10 2020-05-08 Quelantes macrocíclicos y métodos de uso de estos CR20210556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962846044P 2019-05-10 2019-05-10
PCT/IB2020/054381 WO2020229974A1 (en) 2019-05-10 2020-05-08 Macrocyclic chelators and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20210556A true CR20210556A (es) 2021-12-17

Family

ID=70804855

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210556A CR20210556A (es) 2019-05-10 2020-05-08 Quelantes macrocíclicos y métodos de uso de estos

Country Status (22)

Country Link
US (2) US11576986B2 (es)
EP (1) EP3966211A1 (es)
JP (2) JP7734078B2 (es)
KR (1) KR20220006613A (es)
CN (1) CN114127059B (es)
AU (2) AU2020273654B2 (es)
BR (1) BR112021022237A2 (es)
CA (1) CA3139806A1 (es)
CL (1) CL2021002960A1 (es)
CO (1) CO2021015713A2 (es)
CR (1) CR20210556A (es)
DO (1) DOP2021000233A (es)
EA (1) EA202193076A1 (es)
EC (1) ECSP21089217A (es)
IL (1) IL287909A (es)
MA (1) MA55885A (es)
MX (1) MX2021013667A (es)
PE (1) PE20220935A1 (es)
PH (1) PH12021552791A1 (es)
SG (1) SG11202112100PA (es)
UA (1) UA129220C2 (es)
WO (1) WO2020229974A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017281364B2 (en) 2016-06-23 2023-06-22 Cornell University Double targeted constructs to affect tumor kill
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
WO2020106886A1 (en) 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
EP3966206B1 (en) 2019-05-10 2023-08-09 Deciphera Pharmaceuticals, LLC Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
AU2020273654B2 (en) 2019-05-10 2026-04-09 Janssen Biotech, Inc. Macrocyclic chelators and methods of use thereof
EP3966207B1 (en) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
JP7626722B2 (ja) 2019-06-17 2025-02-04 デシフェラ・ファーマシューティカルズ，エルエルシー アミノピリミジンアミドオートファジー阻害剤およびその使用方法
WO2021250240A1 (en) * 2020-06-12 2021-12-16 Orano Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof
EP4243935A1 (en) * 2020-11-10 2023-09-20 Janssen Biotech, Inc. Macrocyclic compounds and methods of use thereof
JP2024503924A (ja) * 2021-01-27 2024-01-29 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用
CN117120433A (zh) * 2021-03-26 2023-11-24 日本医事物理股份有限公司 化合物、化合物的制造方法及保管方法、靶向剂的制造方法、以及组合物
KR20230163487A (ko) * 2021-03-31 2023-11-30 니혼 메디피직스 가부시키가이샤 항egfr 항체의 방사성 복합체 및 방사성 의약
WO2022249089A1 (en) 2021-05-27 2022-12-01 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
EP4380633A2 (en) * 2021-08-02 2024-06-12 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
JP2024125438A (ja) * 2021-08-03 2024-09-19 住友化学株式会社 放射性金属錯体及びその製造方法、並びに放射性金属捕捉剤
KR20240049342A (ko) 2021-08-27 2024-04-16 얀센 바이오테크 인코포레이티드 항-psma 항체 및 이의 용도
MX2024002479A (es) * 2021-08-27 2024-05-28 Janssen Biotech Inc Radioconjugados anti-psma y usos de estos.
CN118317957A (zh) * 2021-09-29 2024-07-09 墨尔本大学 在靶向放射疗法应用中作为配体的含大环的化合物和其放射性标记的络合物
CN118302204A (zh) * 2021-11-09 2024-07-05 詹森生物科技公司 大环化合物及其诊断用途
CA3240194A1 (en) * 2021-11-09 2023-05-19 Edward Cleator Macrocyclic compounds and methods of making the same
JP2025504907A (ja) 2022-01-26 2025-02-19 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用
JP2023135733A (ja) * 2022-03-16 2023-09-29 Ｊｆｅエンジニアリング株式会社 ジルコニウム錯体およびその合成方法
CN114656422B (zh) * 2022-04-22 2023-05-23 重庆理工大学 一种新型氮杂冠醚化合物及其阳离子脂质体、制备方法与应用
CN114874214B (zh) * 2022-05-31 2023-03-21 南京航空航天大学 可偶联巯基的双功能大环螯合剂衍生物及其制备方法
CN114949259B (zh) * 2022-07-11 2023-09-19 重庆理工大学 一种氮杂冠醚结构的基因递送载体及其制备方法和应用
WO2025045168A1 (zh) 2023-09-01 2025-03-06 江苏恒瑞医药股份有限公司 一种大环化合物及其用途
AU2024351474A1 (en) 2023-09-29 2026-05-07 Aktis Oncology, Inc. Miniproteins, conjugates & uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2831073B2 (ja) * 1988-06-24 1998-12-02 ザ ダウ ケミカル カンパニー 大環状二官能キレート剤、その錯体及びそれらの抗体接合体
WO2000059896A1 (en) 1999-03-23 2000-10-12 The United States Of America, Represented By The Secretary, Department Of Health And Human Services 225Ac-HEHA AND RELATED COMPOUNDS, METHODS OF SYNTHESIS AND METHODS OF USE
WO2012012612A2 (en) 2010-07-23 2012-01-26 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
WO2015073746A2 (en) 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research 18f labeling of proteins using sortases
FI3553088T3 (fi) 2013-11-19 2026-04-21 Janssen Biotech Inc Humanisoitu kallikreiini-2-antivasta-aine
HUE049926T2 (hu) 2015-08-11 2020-11-30 Galera Labs Llc Makrociklusos pentaazagyûrûkomplexek orális biológiai hozzáférhetõséggel
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
FR3045606B1 (fr) 2015-12-18 2019-04-05 Ecole Normale Superieure De Lyon Complexes de lanthanide pour la cristallisation de macromolecules biologiques et la determination de leur structure cristallographique
SMT202000249T1 (it) 2016-04-22 2020-07-08 Astrazeneca Ab Inibitori di mcl1 macrociclici per il trattamento di cancro
WO2018031809A1 (en) 2016-08-10 2018-02-15 Cancer Targeted Technology Llc Chelated psma inhibitors
JP2018068834A (ja) * 2016-11-01 2018-05-10 オリンパス株式会社 走査型内視鏡および走査型内視鏡の製造方法
WO2018183906A1 (en) * 2017-03-30 2018-10-04 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
KR102724812B1 (ko) * 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
JP2021502418A (ja) * 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド ポリペプチドを修飾するための組成物及び方法
MX2020006395A (es) 2017-12-18 2020-12-03 Janssen Biotech Inc Radioetiquetado de polipeptidos.
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
WO2020106886A1 (en) * 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
US20220088231A1 (en) 2018-12-03 2022-03-24 Fusion Pharmaceuticals Inc. Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
AU2020273654B2 (en) 2019-05-10 2026-04-09 Janssen Biotech, Inc. Macrocyclic chelators and methods of use thereof
CA3139809A1 (en) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
EP4243935A1 (en) 2020-11-10 2023-09-20 Janssen Biotech, Inc. Macrocyclic compounds and methods of use thereof
JP2024503924A (ja) 2021-01-27 2024-01-29 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用
CA3240194A1 (en) 2021-11-09 2023-05-19 Edward Cleator Macrocyclic compounds and methods of making the same
CN118302204A (zh) 2021-11-09 2024-07-05 詹森生物科技公司 大环化合物及其诊断用途

Also Published As

Publication number Publication date
AU2020273654B2 (en) 2026-04-09
US12453785B2 (en) 2025-10-28
PH12021552791A1 (en) 2022-09-05
CO2021015713A2 (es) 2021-11-30
KR20220006613A (ko) 2022-01-17
US11576986B2 (en) 2023-02-14
CN114127059A (zh) 2022-03-01
US20230110178A1 (en) 2023-04-13
ECSP21089217A (es) 2022-01-31
IL287909A (en) 2022-01-01
DOP2021000233A (es) 2022-07-31
AU2026202492A1 (en) 2026-04-23
SG11202112100PA (en) 2021-11-29
BR112021022237A2 (pt) 2022-03-29
EA202193076A1 (ru) 2022-02-16
WO2020229974A1 (en) 2020-11-19
CA3139806A1 (en) 2020-11-19
CL2021002960A1 (es) 2022-06-24
PE20220935A1 (es) 2022-05-31
AU2020273654A1 (en) 2021-11-25
JP2025176045A (ja) 2025-12-03
MA55885A (fr) 2022-03-16
US20200353105A1 (en) 2020-11-12
MX2021013667A (es) 2022-01-31
EP3966211A1 (en) 2022-03-16
JP2022532157A (ja) 2022-07-13
CN114127059B (zh) 2024-09-24
JP7734078B2 (ja) 2025-09-04
UA129220C2 (uk) 2025-02-12

Similar Documents

Publication Publication Date Title
PH12021552791A1 (en) Macrocyclic chelators and methods of use thereof
EA202090370A1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство
NO20074474L (no) Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav
NL300418I1 (nl) Gebruik van trifunctionele bispecifieke en trispecifieke antilichamen voor de behandeling van maligne ascitis
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
TN2018000419A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof.
EA201171195A8 (ru) Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
EA201792522A1 (ru) Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4
NO20050416L (no) Humaniserte antistoffer mot human 4-1BB
NO20091379L (no) Effektiv syntese av chelatorer for nukleaer bildebehandling og radioterapi: blandinger og anvendelser
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
BR112012020304A2 (pt) complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit
NO830935L (no) Fremgangsmaate for fremstilling av nye konjugater som ved kovalent binding binder sammen et enzym og et antistoff
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
SA519401032B1 (ar) (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه
PH12021553284A1 (en) Prostate specific membrane antigen (psma) ligands and uses thereof
JOP20240260A1 (ar) معقّدات صيدلانية مشعة تستهدف مستضد الغشاء المحدد للبروستات وتوليفات منها
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
WO2005048925A3 (en) Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
ZA202108422B (en) Anti-cd25 for tumour specific cell depletion
PH12022550765A1 (en) Binding molecule specific for lif and use thereof
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.
WO2024123965A3 (en) Methods for treating dll3-expressing cancer
MX2025014729A (es) Anticuerpos de doble union anti-ceacam5/6